Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study

BACKGROUND: Sodium-glucose co-transporter 2 inhibitors (SGLT2 I) has cardiorenal protective properties and are recommended for patients with diabetes and established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Although cardiorenal complications are high in dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Ngai Mui, Ng, Yeung Shing, Chu, Tsun Kit, Lau, Phyllis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730654/
https://www.ncbi.nlm.nih.gov/pubmed/36476327
http://dx.doi.org/10.1186/s12875-022-01928-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730654/
https://www.ncbi.nlm.nih.gov/pubmed/36476327
http://dx.doi.org/10.1186/s12875-022-01928-z

Ejemplares similares